These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 14562856)

  • 1. Managing antiretroviral-associated liver disease.
    Dieterich D
    J Acquir Immune Defic Syndr; 2003 Sep; 34 Suppl 1():S34-9. PubMed ID: 14562856
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hepatic histopathology and clinical characteristics associated with antiretroviral therapy in HIV patients without viral hepatitis.
    Akhtar MA; Mathieson K; Arey B; Post J; Prevette R; Hillier A; Patel P; Ram LJ; Van Thiel DH; Nadir A
    Eur J Gastroenterol Hepatol; 2008 Dec; 20(12):1194-204. PubMed ID: 18989143
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drug-induced liver injury associated with the use of nonnucleoside reverse-transcriptase inhibitors.
    Dieterich DT; Robinson PA; Love J; Stern JO
    Clin Infect Dis; 2004 Mar; 38 Suppl 2():S80-9. PubMed ID: 14986279
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk of severe hepatotoxicity associated with antiretroviral therapy in the HIV-NAT Cohort, Thailand, 1996-2001.
    Law WP; Dore GJ; Duncombe CJ; Mahanontharit A; Boyd MA; Ruxrungtham K; Lange JM; Phanuphak P; Cooper DA
    AIDS; 2003 Oct; 17(15):2191-9. PubMed ID: 14523276
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections.
    Sulkowski MS; Thomas DL; Mehta SH; Chaisson RE; Moore RD
    Hepatology; 2002 Jan; 35(1):182-9. PubMed ID: 11786975
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A comprehensive hepatic safety analysis of nevirapine in different populations of HIV infected patients.
    Stern JO; Robinson PA; Love J; Lanes S; Imperiale MS; Mayers DL
    J Acquir Immune Defic Syndr; 2003 Sep; 34 Suppl 1():S21-33. PubMed ID: 14562855
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hepatotoxicity of antiretroviral drugs in HIV HCV patients with congenital coagulopathies followed at an Haemophilia Unit during a decade.
    Sauleda S; Martorell M; Esteban JI; Tural C; Ruiz I; Puig L; Esteban R; Guardia J; Vargas V
    Haemophilia; 2006 May; 12(3):228-36. PubMed ID: 16643206
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lack of hepatotoxicity associated with nonnucleoside reverse transcriptase inhibitors.
    Palmon R; Koo BC; Shoultz DA; Dieterich DT
    J Acquir Immune Defic Syndr; 2002 Apr; 29(4):340-5. PubMed ID: 11917237
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antiretroviral therapy-related hepatotoxicity: predictors and clinical management.
    Dore G
    J HIV Ther; 2003 Nov; 8(4):96-100. PubMed ID: 14671507
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improving HIV infection management using antiretroviral plasma drug levels monitoring: a clinician's point of view.
    Clevenbergh P; Mouly S; Sellier P; Badsi E; Cervoni J; Vincent V; Trout H; Bergmann JF
    Curr HIV Res; 2004 Oct; 2(4):309-21. PubMed ID: 15544452
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Severe hepatic cytolysis: incidence and risk factors in patients treated by antiretroviral combinations. Aquitaine Cohort, France, 1996-1998. Groupe dEpidémiologie Clinique de Sida en Aquitaine (GECSA).
    Savès M; Vandentorren S; Daucourt V; Marimoutou C; Dupon M; Couzigou P; Bernard N; Mercié P; Dabis F
    AIDS; 1999 Dec; 13(17):F115-21. PubMed ID: 10597772
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk and determinants of developing severe liver toxicity during therapy with nevirapine-and efavirenz-containing regimens in HIV-infected patients.
    Ena J; Amador C; Benito C; Fenoll V; Pasquau F
    Int J STD AIDS; 2003 Nov; 14(11):776-81. PubMed ID: 14624743
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Longitudinal effect of antiretroviral therapy on markers of hepatic toxicity: impact of hepatitis C coinfection.
    French AL; Benning L; Anastos K; Augenbraun M; Nowicki M; Sathasivam K; Terrault NA
    Clin Infect Dis; 2004 Aug; 39(3):402-10. PubMed ID: 15307009
    [TBL] [Abstract][Full Text] [Related]  

  • 14. NNRTI hepatotoxicity: efavirenz versus nevirapine.
    Pulido F; Torralba M
    J HIV Ther; 2002 Nov; 7 Suppl 2():S3-16. PubMed ID: 12735215
    [No Abstract]   [Full Text] [Related]  

  • 15. Risk factors for severe hepatic injury after introduction of highly active antiretroviral therapy.
    Núñez M; Lana R; Mendoza JL; Martín-Carbonero L; Soriano V
    J Acquir Immune Defic Syndr; 2001 Aug; 27(5):426-31. PubMed ID: 11511818
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of liver fibrosis on highly active antiretroviral therapy-associated hepatotoxicity in patients with HIV and hepatitis C virus coinfection.
    Aranzabal L; Casado JL; Moya J; Quereda C; Diz S; Moreno A; Moreno L; Antela A; Perez-Elias MJ; Dronda F; Marín A; Hernandez-Ranz F; Moreno A; Moreno S
    Clin Infect Dis; 2005 Feb; 40(4):588-93. PubMed ID: 15712082
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The nucleoside reverse transcriptase inhibitors, nonnucleoside reverse transcriptase inhibitors, and protease inhibitors in the treatment of HIV infections (AIDS).
    De Clercq E
    Adv Pharmacol; 2013; 67():317-58. PubMed ID: 23886005
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Elevated plasma concentrations of protease inhibitors and nonnucleoside reverse transcriptase inhibitors in patients coinfected with human immunodeficiency virus and hepatitis B or C: case series and literature review.
    Robertson SM; Scarsi KK; Postelnick MJ; Lynch P
    Pharmacotherapy; 2005 Aug; 25(8):1068-72. PubMed ID: 16207097
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Delavirdine: a review of its use in HIV infection.
    Scott LJ; Perry CM
    Drugs; 2000 Dec; 60(6):1411-44. PubMed ID: 11152019
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nucleoside analogue-sparing strategy for the treatment of chronic HIV infection: potential interest and clinical experience.
    Joly V; Yeni P
    Antivir Ther; 2005; 10(1):29-40. PubMed ID: 15751761
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.